Status:
COMPLETED
Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Brief Summary
REALIZE was a single-arm retrospective cohort study which described treatment patterns with brolucizumab, including treatment intervals between anti-vascular endothelial growth factor (VEGF) injection...
Eligibility Criteria
Inclusion
- • Patients aged ≥50 years with a nAMD diagnosis, who received ≥1 brolucizumab prescription regardless of prior anti-VEGF treatment, and had a minimum of 12-month follow-up from index date.
Exclusion
- Patients without a record of prescription of any drug in the six months before the index date (pre-index period).
- Patients with evidence of bilateral treatment with brolucizumab.
Key Trial Info
Start Date :
January 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 29 2022
Estimated Enrollment :
2089 Patients enrolled
Trial Details
Trial ID
NCT06021366
Start Date
January 7 2022
End Date
August 29 2022
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Porto Salvo, Portugal, 2740-255